Our Mission

Empower people to navigate their brain health through early testing.

Our Goals

We believe navigation of brain health is the new frontier in medical science—one that brings a significant impact in a fast-growing aging world population.

Prevention is the secret to health and wellness. Our breakthrough technology enables individuals to track the biomarkers associated with Alzheimer’s and Parkinson’s. We want to empower people with personal biometrics to make informed choices early for preventive brain care.

Team Amprion strives to deepen, enrich, and expand drug research to find the cures for Alzheimer’s and Parkinson’s through scientific advances.

Our Story

Prions are the bad actors that drive many yet incurable diseases. Cracking the code on prions is the key to cure the incurables. Alzheimer’s and Parkinson’s are our top priorities. Here’re some key milestones of our evolving journey…

2007
2007

Once Upon A Time

Neuroscientist Claudio Soto teams up with molecular pathologist Dr. Russ Lebovitz to cofound Amprion. Their mission: to help detect and eliminate Madcow Disease, aka Creutzfeldt-Jakob disease (CJD). Dr. Soto began developing a test assay to detect the prions, aka misfolded proteins, the bad actors driving CJD.

Watch Our Origin Story
2010
2010
Source: UTHealth - Technology developed by Claudio Soto, PhD, can detect misfolded proteins associated with brain diseases. (Photo credit/ Alex Luster with The Storyhive).

The Pivot

Luckily for the humans, Madcow disease dissipates. The Company pivots as the scientists pondered on a fateful question: What if there was a parallel between the misfolded proteins in Madcow disease and the brains of patients with Alzheimer’s, Parkinson’s, or other neurodegenerative disorders?

Watch Prion War
2013
2013

An Aha Moment!

An “Aha!” moment arrives when Dr. Soto proves in his lab that there is indeed a similarity and develops a molecular technology to detect the misfolded protein, Abeta, a biomarker found in most Alzheimer’s patients.

Learn About Our Science
2014
2014

Amprion Was Born!

The Company expanded on Dr. Soto’s technology to detect other misfolded proteins, including Synuclein and Tau. Both types of prions are found in Parkinson’s and Alzheimer’s patients.

Watch The Amprion Story
2015
2015

Our Mission

Amprion embarks on a new mission: To provide clinical tests for doctors to accurately diagnose Alzheimer’s, Parkinson’s, and ParkinZheimer spectrum diseases.

How Amprion Helps YOU
2017
2017

Our Science

Amprion builds an R&D lab, further enhancing its proprietary Prion Testing TechnologySM.

How We Help Doctors Help YOU
2018
2018

Scientists at work

Team Amprion establishes a new clinical laboratory, a state-of-the-art diagnostics lab, run by a full stack of talented scientists, experts, and professionals, not to mention advanced robotics when the humans are off the clock.

Benefits of Biomarker Testing
2019
2019

FDA Breakthrough Designation

The US FDA awards Amprion Breakthrough Device Designation to detect misfolded Synuclein, a biomarker for Parkinson’s. We (and our robots) cheer!

Watch FDA Breakthrough Designation
Feb 2020
Feb 2020

Breakthrough Publishing

Dr. Soto publishes a landmark article in Nature, bolstering the Company’s Prion Testing Technology in distinguishing between different misfolded Synuclein structures related to Parkinson’s and Multiple System Atrophy (MSA). 

Read Our Research Blog On PD Diagnosis
2020
2020

Push Cure Thru Covid!

Team Amprion, wearing masks and standing 6-feet apart, worked through the Covid-pandemic. The team reaches a significant milestone—meeting all approval requirements for CLIA, preparing Amprion to market various clinical tests for Alzheimer’s and Parkinson’s diagnosis.

Discover How Amprion Helps YOU!
2021
2021

Test For Parkinson's & LBD

We’re gearing up for the commercial launch of our first biomarker test to diagnose Parkinson’s, Lewy Body Dementia (LBD), by detecting misfolded Synuclein via CSF. Testing will be available by Q2 2021.

Get Tested Today
I feel like every time a door is opened by science, suddenly there are a hundred doors that need to get opened. That's what makes it an everlasting, interesting experience to go through.”
Alan Alda
Alan Alda
Actor & Advocate For Parkinson's